Dealing with A State of Emergency: A Comparative Study Between Indonesia and Malaysia in Government Use for Pharmaceutical Products

Dewi Sulistianingsih; Yuli Prasetyo Adhi; Diaj Puji Lestari; Rahmawati Binti Mohd Yusoff

doi:10.15294/ildisea.v5i2.29671

Authors

Dewi Sulistianingsih Faculty of Law, Universitas Negeri Semarang Author https://orcid.org/0000-0003-4152-0590
Yuli Prasetyo Adhi Faculty of Law, Diponegoro University Author https://orcid.org/0009-0005-4567-1507
Diah Puji Lestari Faculty of Law, Universitas Negeri Semarang Author
Rahmawati Binti Mohd Yusoff Faculty of Law, UiTM Johor Author https://orcid.org/0000-0003-3991-0143

DOI:

https://doi.org/10.15294/ildisea.v5i2.29671

Keywords:

Government Patent Implementation, Covid-19, Remdesivir, Favipiravir

Abstract

The implementation of patents by the government has become a national policy to control the spread of COVID-19 by helping drug supplies in emergencies and urgent situations. The purpose of this research is to analyse patent regulation by the government (Government Use) for pharmaceutical products in the state of emergency in Indonesia by comparing with Government Use in Malaysia. This research is legal research using secondary data with qualitative analysis. The implementation of patents by the government on the Covid-19 drugs remdesivir and favipiravir, whose application in Indonesia has been based on the provisions regulated by TRIPS and the DOHA Declaration. The implementation of this policy is due to a very urgent need in efforts to tackle the COVID-19 pandemic. Malaysia has also implemented the same policy to address the need to import a generic version of the Hepatitis C drug. It is hoped that the implementation of patents by the Government on the drugs remdesivir and favipiravir can facilitate access for Covid-19 patients who need them and can be an effective strategy to deal with the Covid-19 outbreak.

References

Ali, Feroz. “Nexavar: The First Market-Initiated Compulsory Licence.” NUJS Law Review Juli-Desem (2016): 229–57. https://doi.org/10.2139/ssrn.2729681.

Andrieansjah, Andrieansjah. “The Impact of Covid-19 on Intellectual Property Legal System Related To Public Health in Connection With Trips Flexibilities in Indonesia.” Indonesian Law Journal 13, no. 2 (2020): 165–91. https://doi.org/10.33331/ilj.v13i2.31.

Arab-Zozani, Morteza, Soheil Hassanipour, and Djavad Ghoddoosi-Nejad. “Favipiravir for Treating Patients with Novel Coronavirus (COVID-19): Protocol for a Systematic Review and Meta-Analysis of Randomised Clinical Trials.” BMJ Open 10, no. 7 (2020): 1–3. https://doi.org/10.1136/bmjopen-2020-039730.

Atmaja, Yustisiana Susila, Budi Santoso, and Irawati Irawati. “Pelindungan Hukum Terhadap Paten Produk Farmasi Atas Pelaksanaan Paten Oleh Pemerintah (Government Use).” Masalah-Masalah Hukum 50, no. 2 (2021): 196–208. https://doi.org/10.14710/mmh.50.2.2021.196-208.

Azmi, Ida Madieha. “Intellectual Property Policy and Academic Patenting in Malaysia: Challenges and Prospects.” Pertanika Journal of Social Science and Humanities 22, no. January (2014): 1–20.

Cindawati. “Prinsip Good Faith(Itikad Baik) Dalam Hukum Kontrak Bisnis Internasional.” Mimbar Hukum - Fakultas Hukum Universitas Gadjah Mada 26, no. 2 (2014): 181. https://doi.org/10.22146/jmh.16038.

Darma Pertiwi, Evi. “Pelindungan Hak Akses Kesehatan Atas Perubahan Ketentuan Lisensi-Wajib Dalam Undang-Undang Cipta Kerja.” Jurnal Lex Renaissance 7, no. 1 (2022): 100–113. https://doi.org/10.20885/jlr.vol7.iss1.art8.

Eka An Aqimuddin, Iman Sunendar, Frency Siska, Rahmat J. Tanjung, Mayas M. “Tinjauan Pendekatan Hukum Dan Ekonomi Terhadap Model Lisensi Wajib Paten Atas Obat Dalam Wto-Trips Dan Deklarasi Doha 2001.” In Prosiding Seminar Nasional Penelitian Dan PKM Sosial, Ekonomi Dan Humaniora, 1–13, 2015.

Frontieres, Médecins Sans. “Compulsory Licenses, the TRIPS Waiver, and Access to COVID-19 Medical Technologies,” 2021.

Hakim, Luqman. “Implementasi Lisensi Wajib TRIPs Agreement Dalam Produk Farmasi Di Negara Swedia.” Jurnal Hukum Lex Generalis 4, no. 1 (2023): 28–58. https://doi.org/10.56370/jhlg.v4i1.349.

Hingun, Mohsin, and Rahamatthunnisa Mohamed Nizamuddin. “Amending Section 84 Patents Act 1983 To Encompass the Health Flexibilities Leverage Accorded By Article 31Bis Trips Agreement.” UUM Journal of Legal Studies 11, no. 2 (2020): 1–26. https://doi.org/10.32890/uumjls.11.2.2020.8052.

Ichsan, Achmad Amri. “Analisis Yuridis Terhadap Lisensi Wajib Dan Pelaksanaan Paten Oleh Pemerintah Berdasarkan Perjanjian TRIP’s.” Jurnal Ilmu Hukum Legal Opinion 2, no. 1 (2014): 1–12.

Kapczynski, Amy, and Aaron S. Kesselheim. “‘Government Patent Use’: A Legal Approach to Reducing Drug Spending.” Health Affairs 35, no. 5 (2016): 791–97. https://doi.org/10.1377/hlthaff.2015.1120.

Kurnianingrum, Trias Palupi. “Pelindungan Hak Paten Atas Pengetahuan Obat Tradisional Melalui Pasal 26 UU No. 13 Tahun 2016 Tentang Paten (Protection of Patent Rights on Traditional Medicine Knowledge Through Article 26 of Law No. 13 of 2016 Concerning Patents).” Negara Hukum: Membangun Hukum Untuk Keadilan Dan Kesejahteraan 10, no. 1 (2019): 49–65. https://doi.org/10.22212/jnh.v10i1.1222.

Lestari, Sartika Nanda. “Implementasi Compulsory Licensing Terhadap Obat-Obatan Dalam Bidang Farmasi Di Indonesia.” Diponegoro University, 2012.

Marzuki, Mahmud Peter. Penelitian Hukum: Edisi Revisi. Revisi. Jakarta: Kencana Prenada Media Grup, 2017.

Mercurio, Bryan C. “TRIPs , Patents , and Access To Life- Saving Drugs in the Developing World.” Marquette Intellectual Property Law Review 8, no. 2 (2004): 211–53.

Mike Ho Mun Keat, Shearn Delamore & Co. “Government Rights Over Patented Inventions In Malaysia.” Conventuslaw.Com, October 2018. https://conventuslaw.com/report/government-rights-over-patented-inventions-in/.

Muis, Lidya Shery. “Hak Atas Aksesibilitas Obat Paten Bagi Masyarakat.” Widya Pranata Hukum : Jurnal Kajian Dan Penelitian Hukum 1, no. 1 (2019): 36–64. https://doi.org/10.37631/widyapranata.v1i1.259.

Perehudoff, Katrina, Ellen Thoen, and Pascale Boulet. “Overriding Drug and Medical Technology Patents for Pandemic Recovery: A Legitimate Move for High-Income Countries, Too.” BMJ Global Health 6, no. 4 (2021): 10–13. https://doi.org/10.1136/bmjgh-2021-005518.

Raden Bagoes Prasetyo Raharjo, Kholis Roisah. “Hak Akses Kesehatan Masyarakat Terhadap Hak Paten Produk Farmasi.” USM Law Review 4, no. 2 (2021): 604–13. https://doi.org/10.14710/mmh.50.2.2021.196-208.

Samariadi. “Implementation of Compulsory Licensing of Pharmaceutical Patents in Indonesia Is Associated With DOHA Declaration on The TRIPs Agreement and Public Health.” De Lega Lata I, no. Juli-Desember 2016 (2016): 448–65.

Sitorus, Winner. “Kepentingan Umum Dalam Perlindungan Paten.” Yuridika 29, no. 1 (2014): 39–60. https://doi.org/10.20473/ydk.v29i1.357.

Utomo, Tomi Suryo. “Doha Declaration in The Perspective of Cheap and Affordable Drug Access: A Complement to the TRIPS" Agreement.” Unisia 30, no. 64 (2007): 122–32.

Wibawa, Puguh Toko Arisanto & Adi. “Implementasi Developmental State India Dalam Menghadapi Paten Trips Dan Strategi Ranbaxy Lab. Dalam Persaingan Global.” Jurnal Transborder 3, no. 1 (2019): 43–58.

Yustisiana Susila Atmaja, Budi Santoso, Irawati Irawati. “Pelindungan Hukum Terhadap Paten Produk Farmasi Atas Pelaksanaan Paten Oleh Pemerintah (Government Use).” Masalah-Masalah Hukum 50, no. 2 (2021): 196–208. https://doi.org/https://doi.org/10.14710/mmh.50.2.2021.196-208.